...
ERASMID

Erasca, Inc.

HealthcareBiotechnology
$13.66
$0.00(+0.66%)
52W$1.01
$14.17
Updated Mar 2, 12:00 AM
RSI76
RS Rating98/99
Beta0.97
Volatility99%
F-Score2/9
Mkt Cap$3.9B
STAGE 2 UPTREND

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

STAGE 2 UPTREND

Erasca, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 98), indicating clear outperformance against the broad market. However, with RSI at 76, the stock is extended and may be prone to a short-term pullback.

Relative Strength
98
out of 99
Market Leader
Trend Score
4/4
Minervini Criteria
STAGE 2 UPTREND
Risk (Beta)
0.97
vs S&P 500
MARKET
52W Position
96%
from 52W low
Near High
Trend & Momentum Analysis

Trend Template (Minervini)

STAGE 2 UPTREND4/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$8.79
50 SMA > 100 SMA$5.75
100 SMA > 150 SMA$4.39
150 SMA > 200 SMA$3.65

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$12.19+12.06%ABOVE
50 SMA$8.79+55.42%ABOVE
100 SMA$5.75+137.58%ABOVE
150 SMA$4.39+211.13%ABOVE
200 SMA$3.65+274.33%ABOVE

Price Performance

1D+0.7%
1W+4.9%
1M+34.8%
3M+330.9%
6M+7.7%
YTD+280.5%
1Y+9.0%
3Y+56.0%
52-Week Trading Range96% from low
$13.66
52W Low$1.01
52W High$14.17

Technical Indicators

RSI (14)OVERBOUGHT
75.8
305070
VCP ScoreHOT
7/10
Base depth: 83.2%

Risk Profile

Beta
0.97
52W Vol
99%
ATR
$0.74
Max DD (1Y)
-32%

Volume Analysis

Today
13
50D Avg
5.68M
Vol Ratio
0.00x
Liquidity
MODERATE

Earnings Momentum

Q4'24+45%
$-0.11
Q1'25+52%
$-0.11
Q2'25+59%
$-0.12
Q3'25
$-0.11
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:
5 Years:
3 Years:
TTM:

Compounded Profit Growth

10 Years:
5 Years:
3 Years:
TTM:+45.78%

Stock Price CAGR

10 Years:-2.41%
5 Years:-4.76%
3 Years:+55.97%
1 Year:+8.97%

Return on Equity

10Y Avg:-78.8%
5Y Avg:-78.8%
3Y Avg:-44.6%
Last Year:-36.7%

Key Metrics

Market Cap$3.9B
Gross Margin
Net Margin
Piotroski F-Score2/9

Frequently Asked Questions

Is ERAS in an uptrend right now?

ERAS has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, ERAS is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.

Is ERAS overbought or oversold?

ERAS's RSI (14) is 76. The stock is in overbought territory (RSI > 70), which may signal a pullback.

Is ERAS outperforming the market?

ERAS has a Relative Strength (RS) Rating of 98 out of 99. Yes, ERAS is a market leader, outperforming 98% of all stocks over the past 12 months.

Where is ERAS in its 52-week range?

ERAS is trading at $13.66, which is 96% of its 52-week high ($14.17) and 96% above its 52-week low ($1.01).

How volatile is ERAS?

ERAS has a Beta of 0.97 and 52-week volatility of 99%. It's less volatile than the S&P 500 - generally more stable.